髓系白血病
生物
鸟嘌呤
核苷酸
转录因子
癌症研究
融合蛋白
白血病
基因
化学
生物化学
细胞生物学
遗传学
重组DNA
作者
Xiangguo Shi,Minhua Li,Zian Liu,Jonathan Tiessen,Yuan Li,Jing Zhou,Yudan Zhu,Swetha Mahesula,Ding Qing,Lin Tan,Mengdie Feng,Yuki Kageyama,Yusuke Hara,Jacob J. Tao,Xuan Luo,Kathryn A. Patras,Philip L. Lorenzi,Suming Huang,Alexandra M. Stevens,Koichi Takahashi
标识
DOI:10.1038/s41467-025-57544-9
摘要
Abstract Targeting the dependency of MLL -rearranged ( MLL r) leukemias on menin with small molecule inhibitors has opened new therapeutic strategies for these poor-prognosis diseases. However, the rapid development of menin inhibitor resistance calls for combinatory strategies to improve responses and prevent resistance. Here we show that leukemia stem cells (LSCs) of MLL r acute myeloid leukemia (AML) exhibit enhanced guanine nucleotide biosynthesis, the inhibition of which leads to myeloid differentiation and sensitization to menin inhibitors. Mechanistically, targeting inosine monophosphate dehydrogenase 2 (IMPDH2) reduces guanine nucleotides and rRNA transcription, leading to reduced protein expression of LEDGF and menin. Consequently, the formation and chromatin binding of the MLL-fusion complex is impaired, reducing the expression of MLL target genes. Inhibition of guanine nucleotide biosynthesis or rRNA transcription further suppresses MLL r AML when combined with a menin inhibitor. Our findings underscore the requirement of guanine nucleotide biosynthesis in maintaining the function of the LEDGF/menin/MLL-fusion complex and provide a rationale to target guanine nucleotide biosynthesis to sensitize MLL r leukemias to menin inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI